389 related articles for article (PubMed ID: 29907809)
1. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
Shimoni A; Labopin M; Lorentino F; Van Lint MT; Koc Y; Gülbas Z; Tischer J; Bruno B; Blaise D; Pioltelli P; Afanasyev B; Ciceri F; Mohty M; Nagler A
Leukemia; 2019 Jan; 33(1):230-239. PubMed ID: 29907809
[TBL] [Abstract][Full Text] [Related]
2. The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients.
Khanuntong S; Kuptawintu P; Upaisilpsathaporn K; Poolchareon A; Bunworasate U; Hirankarn N
HLA; 2016 Jun; 87(6):422-31. PubMed ID: 27273744
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide.
Ruggeri A; Labopin M; Bacigalupo A; Gülbas Z; Koc Y; Blaise D; Bruno B; Irrera G; Tischer J; Diez-Martin JL; Castagna L; Ciceri F; Mohty M; Nagler A
Cancer; 2018 Apr; 124(7):1428-1437. PubMed ID: 29360162
[TBL] [Abstract][Full Text] [Related]
4. Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin-like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia.
Yahng SA; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Kim HJ
Biol Blood Marrow Transplant; 2016 Feb; 22(2):316-323. PubMed ID: 26415557
[TBL] [Abstract][Full Text] [Related]
5. Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.
Rocha V; Ruggeri A; Spellman S; Wang T; Sobecks R; Locatelli F; Askar M; Michel G; Arcese W; Iori AP; Purtill D; Danby R; Sanz GF; Gluckman E; Eapen M;
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1284-1289. PubMed ID: 27090957
[TBL] [Abstract][Full Text] [Related]
6. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.
Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T
Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027
[TBL] [Abstract][Full Text] [Related]
8. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
9. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.
Willem C; Makanga DR; Guillaume T; Maniangou B; Legrand N; Gagne K; Peterlin P; Garnier A; Béné MC; Cesbron A; Le Bourgeois A; Chevallier P; Retière C
J Immunol; 2019 Apr; 202(7):2141-2152. PubMed ID: 30787107
[TBL] [Abstract][Full Text] [Related]
10. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
[TBL] [Abstract][Full Text] [Related]
11. Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT.
Canaani J; Savani BN; Labopin M; Huang XJ; Ciceri F; Arcese W; Tischer J; Koc Y; Bruno B; Gülbas Z; Blaise D; Maertens J; Ehninger G; Mohty M; Nagler A
Haematologica; 2017 Jun; 102(6):1066-1074. PubMed ID: 28255020
[TBL] [Abstract][Full Text] [Related]
12. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Sanz J; Galimard JE; Labopin M; Afanasyev B; Angelucci E; Ciceri F; Blaise D; Cornelissen JJ; Meijer E; Diez-Martin JL; Koc Y; Rovira M; Castagna L; Savani B; Ruggeri A; Nagler A; Mohty M;
J Hematol Oncol; 2020 May; 13(1):46. PubMed ID: 32375860
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST.
Byrnes CP; Hastings A; Lacej I; Palanicawandar R; Olavarria E; Anand A
HLA; 2024 Jan; 103(1):e15214. PubMed ID: 37712429
[TBL] [Abstract][Full Text] [Related]
15. Donor Selection Based on Killer Cell Immunoglobulin-Like Receptor (KIR) Genotype May Improve Outcome After T-Cell-Replete Haploidentical Transplantation.
Torío A; Pascual MJ; Vidales I; Ortiz M; Caballero A; Heiniger AI
Transplant Proc; 2018 Mar; 50(2):679-682. PubMed ID: 29579887
[TBL] [Abstract][Full Text] [Related]
16. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients.
Kaynar L; Demir K; Turak EE; Öztürk ÇP; Zararsız G; Gönen ZB; Gökahmetoğlu S; Şıvgın S; Eser B; Köker Y; Solmaz M; Ünal A; Çetin M
Hematology; 2017 Apr; 22(3):136-144. PubMed ID: 27724812
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
[TBL] [Abstract][Full Text] [Related]
18. Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.
Lorentino F; Labopin M; Ciceri F; Vago L; Fleischhauer K; Afanasyev B; Kröger N; Cornelissen JJ; Lovira M; Meijer E; Vitek A; Elmaagacli A; Blaise D; Ruggeri A; Chabannon C; Nagler A; Mohty M;
Leukemia; 2021 Feb; 35(2):585-594. PubMed ID: 32409688
[TBL] [Abstract][Full Text] [Related]
19. Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.
Wanquet A; Bramanti S; Harbi S; Fürst S; Legrand F; Faucher C; Granata A; Calmels B; Lemarie C; Picard C; Chabannon C; Weiller PJ; Castagna L; Blaise D; Devillier R
Biol Blood Marrow Transplant; 2018 Mar; 24(3):549-554. PubMed ID: 29247781
[TBL] [Abstract][Full Text] [Related]
20. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Shimoni A; Vago L; Bernardi M; Yerushalmi R; Peccatori J; Greco R; Shem-Tov N; Lo Russo A; Danylesko I; Apel A; Bonini C; Lupo Stanghellini MT; Nagler A; Ciceri F
Am J Hematol; 2017 Oct; 92(10):1011-1019. PubMed ID: 28631269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
